An expanding, diversifying clinical pipeline

PharmaEssentia’s clinical pipeline reflects our hematology/oncology focus, with candidates across a range of indications in development around the world. Building on our innovative science, we intend to expand into other areas where our technology can address needs and support improved outcomes.

Ropeginterferon alfa-2b (P1101) is an investigational therapy not approved for use in the U.S.